Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. NUVL has several positive signals and is within a rising trend, so we believe it will perform strongly in the next couple of days or weeks. We therefore hold a positive evaluation of this stock. Our analysis conclusion for this stock is a Strong Buy candidate.
NUVL stock price ended at $73.49 on Friday, after rising0.36%
The Nuvalent Inc stock price increased by 0.36% on the last trading day (23 May 2025), rising from 72.02 to 73.49. Throughout the last trading session, the stock experienced a fluctuation of 2.82% , ranging from a day low of $72.02 to a day high of 74.05. The price has declined in 6 of the last 10 days, resulting in a total change of 5.21% during this period. On the last day, trading volume decrease by 21.76K shares, with the rising prices. This could serve as an early warning, indicating that risk may slightly increase in the coming days. In total, 359.04K shares were traded, amounting to approximately 26.31M.
NUVL Technical Signals
NUVL(Nuvalent Inc Corp) has 3 buy signals and 0 sell signals now. The current trend is consolidation starting from 2025-05-20. The total price change during this trend is -3.15%. Recently, the price has increased significantly with an increase in volume, indicating a strong bullish signal. The average turnover of NUVL over the last 5 trading days is 25.79M. Overall, the technical indicator signals lean more toward a Bullish outlook in the mid-term.
NUVL Moving Average Analysis
Nuvalent Inc's overall moving average trend leans more bearish as of Saturday, May 24, 2025, with 2 negative signals and 2 positive signal. In the mid-term, the SMA_20 being above the SMA_60 signals a strong bullish trend. There will be some resistance from the lines at $77.19846, and $80.05199999999999. A break-up above any of these levels will issue buy signals. There will be some support from the lines at $67.96553999999999, and $65.112. A break-down below any of these levels will issue sell signals.
NUVL Short Selling Analysis
The short sale ratio of Nuvalent Inc(NUVL) as of 16 May 2025 is 21.49%, rising from last trading day. With increasing price from 71.00 to 73.32. The short sell activity indicate that short sellers may be anticipating a price reversion.
Technical Signal
Technical Signals Summary
Sell
0
Buy
3
Moving Average
Swing
Negative
Stock Price Below SMA_5
Short Term
Positive
SMA_5 Above SMA_20
Mid Term
Positive
SMA_20 Above SMA_60
Long Term
Negative
SMA_60 Below SMA_200
Short Selling
Close Price
Short Sale Ratio
Short Sale Volume
3 Bullish Signals
3 Bullish Signals
When Value satisfies Signal, Indicator signals Bullish
Indicators
Signal
Value
Meaning
Awesome Oscillator (5, 34)
AO_5_34 > 0
2.622
Bullish
Momentum (10 days)
MOM_10 > 0
3.64
Bullish
Moving Average Convergence Divergence (12, 26, 9)
MACD_12_26_9 > 0
0.435
Bullish
0 Bearish Signals
0 Bearish Signals
When Value satisfies Signal, Indicator signals Bearish
No Data
NUVL Price Prediction & Forecast by Similar Chart Analysis
Based on historical patterns and backtesting of stocks with similar movements to Nuvalent Inc(NUVL), our algorithm predicts NUVL's 1-month price at $75.78, with an 3.36%upwardshift. Using a similarity score up to 94.56%and other factors, This forecast updates weekly, adjusting for significant deviations.
Similar Chart
The price prediction chart for Nuvalent Inc (NUVL.O) stock, as of Sunday, May 18, 2025 , forecasts a 3.36% change over the next month, based on its high correlation with ACXP.O stock patterns. The similarity between their price movements over the analyzed periods is 94.56%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
NUVL
No Data
ACXP
Up: 3.36%Similarity: 94.56%
Name
Similarity
Up/Down
ACXP.O
94.56%
+3.36%
IMNM.O
94.02%
+5.33%
SRRK.O
93.98%
-1.80%
RARE.O
93.95%
+0.14%
ENTA.O
93.91%
+1.04%
AGIO.O
93.65%
+2.12%
ZBIO.O
93.54%
+9.17%
AGRO.N
93.54%
+6.49%
PTC.O
93.36%
+2.26%
DLTR.O
93.27%
-17.21%
NUVL Seasonality Analysis
Based on NUVL's historical stock price data across all years, the probability of a positive return in May is25.00%, suggesting it maynotbe an ideal month to invest in NUVL. In contrast,Juneoffers the highest probability of positive returns at100.00%, making it a potentially strong month for investment.
However, this is only a prediction based on one method, and a comprehensive assessment of the stock's future trend should consider additional factors. Our final stock price commentary incorporates three main evaluation dimensions: technical signals, Moving Average trends, and similar chart pattern matching, with the first two dimensions carrying the primary weight to ensure a more robust and accurate forecast.
Monthly Seasonality
The radar chart shows that buying Nuvalent Inc (NUVL.O) stock in June has the highest probability of a positive return (100.00%), while March has the lowest probability (0.00%).
Performance Seasonality
The chart shows Nuvalent Inc. (NUVL)'s annual stock price return for the past three years, helping you analyze price trends and identify recurring trends on an annual basis.
People Also Watch
FAQ
Should I buy Nuvalent Inc (NUVL.O) stock?
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. NUVL has several positive signals and is within a rising trend, so we believe it will perform strongly in the next couple of days or weeks. We therefore hold a positive evaluation of this stock. Our analysis conclusion for this stock is a Strong Buy candidate.
Which months have the highest win rate for buying Nuvalent Inc (NUVL.O) stock in a year?
The radar chart shows that buying Nuvalent Inc (NUVL.O) stock in June has the highest probability of a positive return (100.00%), while March has the lowest probability (0.00%).
How has Nuvalent Inc. (NUVL)'s stock price performed over the past three years?
NUVL's stock price rose by 154.02% in 2023,increased by 2.86% in 2024, and went down by 8.13% in 2025.
Is NUVL a buy based on overall technical signals summary?
NUVL has 3 buy signals and 0 sell signals now. Overall the technical rating for NUVL is Buy . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of NUVL.
What is the trend of Nuvalent Inc (NUVL)'s moving average?
Nuvalent Inc's overall moving average trend leans more bearish as of May 24 2025, with 2 negative signals and 2 positive signal.
What is price prediction for NUVL stock next month?
The price prediction chart for Nuvalent Inc (NUVL.O) stock, as of May 18 2025, forecasts a 3.36% change over the next month, based on its high correlation with ACXP stock patterns. The similarity between their price movements over the analyzed periods is 94.56%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
What is price prediction 2025 for NUVL Stock?
The price prediction for NUVL stock in 2025 is expected to reach **$85-$95** due to UBS's upgrade to Buy with a $116.87 target and increased institutional ownership. The stock is currently undervalued with a price of $72.88, supported by positive institutional movements and a strong pipeline.
What is price prediction 2030 for NUVL Stock?
### **Price Prediction for NUVL Stock by 2030**
1. **Bullish Scenario**: NUVL stock could reach **$150 - $170** by 2030, driven by successful pipeline advancements and potential FDA approvals, particularly for its ROS1 inhibitor, which has shown strong clinical trial results.
2. **Moderate Scenario**: A more realistic target could be **$100 - $120**, considering current valuations and the biotech sector's volatility.
3. **Bearish Scenario**: If key trials fail or market conditions deteriorate, the stock may stabilize around **$70 - $80**, reflecting its current fundamentals and insider activity.
**Reasons**:
- **Pipeline Potential**: NUVL's focus on targeted therapies, especially in oncology, positions it well for long-term growth.
- **Insider and Institutional Activity**: Mixed sentiment among insiders and institutions suggests caution, but UBS's recent upgrade to "Buy" indicates confidence.
- **Valuation Risks**: High forward multiples and negative earnings highlight the need for execution on key milestones.